exelixis inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report exelixis inc  product pipeline review   published by global markets direct product code  published may   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license exelixis inc  product pipeline review   published may   content info  pages description global markets directs exelixis inc  product pipeline review   provides an overview of the exelixis incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of exelixis incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of exelixis inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of exelixis incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the exelixis incs pipeline products reasons to buy evaluate exelixis incs strategic position with total access to detailed information on its product pipeline assess the growth potential of exelixis inc in its therapy areas of focus identify new drug targets and therapeutic classes in the exelixis incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of exelixis inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of exelixis inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of exelixis inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures exelixis inc snapshot exelixis inc overview key information key facts exelixis inc  research and development overview key therapeutic areas exelixis inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  outlicensed products outlicensed productscombination treatment modalities exelixis inc  pipeline products glance exelixis inc  late stage pipeline products phase iii productscombination treatment modalities exelixis inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities exelixis inc  early stage pipeline products preclinical productscombination treatment modalities exelixis inc  drug profiles cabozantinib smalate product description mechanism of action rd progress xl product description mechanism of action rd progress small molecules to agonize spr for autoimmune diseases product description mechanism of action rd progress xl product description mechanism of action rd progress exelixis inc  pipeline analysis exelixis inc  pipeline products by target exelixis inc  pipeline products by route of administration exelixis inc  pipeline products by molecule type exelixis inc  pipeline products by mechanism of action exelixis inc  recent pipeline updates exelixis inc  dormant projects exelixis inc  discontinued pipeline products discontinued pipeline product profiles xl xl xl xl xl exelixis inc  company statement exelixis inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables exelixis inc key information exelixis inc key facts exelixis inc  pipeline by indication  exelixis inc  pipeline by stage of development  exelixis inc  monotherapy products in pipeline  exelixis inc  outlicensed products in pipeline  exelixis inc  outlicensed products combination treatment modalities  exelixis inc  phase iii  exelixis inc  phase ii  exelixis inc  phase i  exelixis inc  preclinical  exelixis inc  pipeline by target  exelixis inc  pipeline by route of administration  exelixis inc  pipeline by molecule type  exelixis inc  pipeline products by mechanism of action  exelixis inc  recent pipeline updates  exelixis inc  dormant developmental projects exelixis inc  discontinued pipeline products  exelixis inc subsidiaries list of figures exelixis inc  pipeline by top  indication  exelixis inc  pipeline by stage of development  exelixis inc  monotherapy products in pipeline  exelixis inc  outlicensed products in pipeline  exelixis inc  pipeline by top  target  exelixis inc  pipeline by top  route of administration  exelixis inc  pipeline by top  molecule type  exelixis inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved market report exelixis inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing exelixis inc  product pipeline review   may    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents request details related global markets directs exelixis inc  product pipeline review   provides an overview of the exelixis incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of exelixis incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of exelixis inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of exelixis incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the exelixis incs pipeline productsreasons to buyevaluate exelixis incs strategic position with total access to detailed information on its product pipelineassess the growth potential of exelixis inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the exelixis incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of exelixis inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of exelixis incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of exelixis inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contentslist of tableslist of figuresexelixis inc snapshotexelixis inc overviewkey informationkey factsexelixis inc  research and development overviewkey therapeutic areasexelixis inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapypipeline products  outlicensed productsoutlicensed productscombination treatment modalitiesexelixis inc  pipeline products glanceexelixis inc  late stage pipeline productsphase iii productscombination treatment modalitiesexelixis inc  clinical stage pipeline productsphase ii productscombination treatment modalitiesphase i productscombination treatment modalitiesexelixis inc  early stage pipeline productspreclinical productscombination treatment modalitiesexelixis inc  drug profilescabozantinib smalateproduct descriptionmechanism of actionrd progressxlproduct descriptionmechanism of actionrd progresssmall molecules to agonize spr for autoimmune diseasesproduct descriptionmechanism of actionrd progressxlproduct descriptionmechanism of actionrd progressexelixis inc  pipeline analysisexelixis inc  pipeline products by targetexelixis inc  pipeline products by route of administrationexelixis inc  pipeline products by molecule typeexelixis inc  pipeline products by mechanism of actionexelixis inc  recent pipeline updatesexelixis inc  dormant projectsexelixis inc  discontinued pipeline productsdiscontinued pipeline product profilesxlxlxlxlxlexelixis inc  company statementexelixis inc  locations and subsidiarieshead officeother locations  subsidiariesappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimerlist of tablesexelixis inc key informationexelixis inc key factsexelixis inc  pipeline by indication exelixis inc  pipeline by stage of development exelixis inc  monotherapy products in pipeline exelixis inc  outlicensed products in pipeline exelixis inc  outlicensed products combination treatment modalities exelixis inc  phase iii exelixis inc  phase ii exelixis inc  phase i exelixis inc  preclinical exelixis inc  pipeline by target exelixis inc  pipeline by route of administration exelixis inc  pipeline by molecule type exelixis inc  pipeline products by mechanism of action exelixis inc  recent pipeline updates exelixis inc  dormant developmental projectsexelixis inc  discontinued pipeline products exelixis inc subsidiarieslist of figuresexelixis inc  pipeline by top  indication exelixis inc  pipeline by stage of development exelixis inc  monotherapy products in pipeline exelixis inc  outlicensed products in pipeline exelixis inc  pipeline by top  target exelixis inc  pipeline by top  route of administration exelixis inc  pipeline by top  molecule type exelixis inc  pipeline products by top  mechanism of action  this report does not have a list of companies mentioned available this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc exelixis inc  office in south san francisco foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingexelixis incofficeeast of  south san franciscosavesharetipsphotos exelixis incno tips and reviewslog in to leave a tip herepostno tips yetwrite a short note about what you liked what to order or other helpful advice for visitors photorelated searchesexelixis inc south san francisco  exelixis inc south san francisco photos  exelixis inc south san francisco location  exelixis inc south san francisco address  exelixis inc south san francisco  exelixis inc south san francisco  exelixis inc south san francisco  exelixis inc east of  south san franciscoaboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in south san franciscoabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfexelixis inc e grand avesouth san francisco ca united statesget directions likely open see when people check inpeople tend to check in during these timestoday am– pmsat–sunnonemon am– pmtue am– pmwed am– pmthu am– pmsee moreunited states » san mateo county » south san francisco » east of professional  other places » officeis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one exelixis inc company information  drugscom skip to content search all allconsumerprofessionalpill idinteractionsnewsfda alertsapprovalspipelineclinical trialscare notesencyclopediadictionarynatural products browse all medications a b c d e f g h i j k l m n o p q r s t u v w x y z advanced search topics  tools facebook twitter google plus sign in sign in register menu home › pharmaceutical companies › exelixis inc print share exelixis inc address exelixis inc  e grand ave south san francisco ca contact detailsphone  website wwwexelixiscomcareers wwwexelixiscomcareers drugs associated with exelixis incexelixis inc manufactures markets andor distributes more than  drugs in the united states medications listed here may also be marketed under different names in different countries nonus country and region specific information is not available on this page brandgeneric name average user rating cabometyx generic name cabozantinib class multikinase inhibitors vegfvegfr inhibitors na cometriq generic name cabozantinib class multikinase inhibitors vegfvegfr inhibitors      cotellic generic name cobimetinib class multikinase inhibitors na latest drug information updates vosevi vosevi sofosbuvir  velpatasvir  voxilaprevir is a singletablet regimen for the treatment of adults withnerlynx nerlynx neratinib is a tyrosine kinase inhibitor for the extended adjuvant treatment of patients with earlytremfya tremfya guselkumab is an interleukin blocker indicated for the treatment of adult patients withbevyxxa bevyxxa betrixaban is an oral oncedaily factor xa inhibitor anticoagulant for the extendeddurationrituxan hycela rituxan hycela rituximab and hyaluronidase human is a subcutaneous monoclonal antibody and hyaluronidasebaxdela baxdela delafloxacin is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin more drug information updates drugscom mobile apps the easiest way to lookup drug information identify pills check interactions and set up your own personal medication records available for android and ios devices explore apps support help center frequent questions sitemap contact us about about drugscom advertising policy content submissions drugscom blog terms  privacy editorial policy privacy policy terms of use attribution  citations facebook twitter google plus youtube rss feed subscribe to receive email notifications whenever new articles are published drugscom provides accurate and independent information on more than  prescription drugs overthecounter medicines and natural products this material is provided for educational purposes only and is not intended for medical advice diagnosis or treatment data sources include micromedex® updated july th  cerner multum™ updated july th  wolters kluwer™ updated july th  and others to view content sources and attributions please refer to our editorial policy third party advertising we comply with the honcode standard for trustworthy health information  verify here copyright   drugscom all rights reserved share on facebook share on twitter share on googleplus email to a friend hide job opportunities  exelixis notice to recruitersstaffing agencies recruiters and staffing agencies should not contact exelixis inc through this page we require that all recruiters and staffing agencies have a signed contract on file any resumes submitted through the web site or directly by recruiters or staffing agencies will be considered unsolicited and the company will not be responsible for any related fees about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site careers job opportunities  exelixis inc    website design hane chow inc privacy terms of use investors  media  exelixis about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site investors  media management and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir  exelixis inc    website design hane chow inc privacy terms of use management  exelixis management members of the exelixis management team left to right pj haley mba senior vice president commercial laura dillard senior vice president human resources dana aftab phd executive vice president evp business operations peter lamb phd evp scientific strategy and chief scientific officer michael m morrissey phd president and chief executive officer christopher j senner evp and chief financial officer gisela m schwab md president product development and medical affairs and chief medical officer jeffrey j hessekiel jd evp and general counsel susan hubbard evp public affairs and investor relations our leadership team is united by an unwavering commitment to creating value through the development of innovative new therapies to improve the treatment of cancer bringing together years of industry experience our dedicated team shares the same vision to create therapies that make a meaningful difference in the lives of patients michael m morrissey phd president and chief executive officer gisela m schwab md president product development and medical affairs and chief medical officer christopher j senner executive vice president and chief financial officer dana aftab phd executive vice president business operations laura dillard senior vice president human resources pj haley mba senior vice president commercial jeffrey j hessekiel jd executive vice president and general counsel susan hubbard executive vice president public affairs and investor relations peter lamb phd executive vice president scientific strategy and chief scientific officer about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site about us managementmichael m morrissey gisela m schwab christopher j senner dana aftab laura dillard pj haley jeffrey j hessekiel susan hubbard peter lamb board of directors collaborations locations contact us  exelixis inc    website design hane chow inc privacy terms of use pipeline  exelixis pipeline the exelixis pipeline includes our lead compounds cabozantinib and cobimetinib as well as other programs that are the subject of partnerships and collaborations with other biopharmaceutical companies an additional whollyowned compound xl is the subject of ongoing clinical research through our investigatorsponsored trial program safety and efficacy for these compounds in the unapproved uses or indications described below have not yet been established cabozantinib exelixis focuses its internal development efforts primarily upon cabozantinib a targeted agent that inhibits the activity of receptor tyrosine kinases including met axl vegf receptors and ret these receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis metastasis tumor angiogenesis and maintenance of the tumor microenvironment exelixis discovered cabozantinib internally and maintains exclusive rights to commercialize the product in the united states outside of the united states ipsen has exclusive commercialization and development rights for current and future cabozantinib indications except in japan where exelixis has granted exclusive rights to takeda exelixis and its partners are collaborating on the global development plan for cabozantinib and ipsen and takeda are responsible for the development work supporting cabozantinib in their respective regions for information on approved uses of cabozantinib please visit our medicines page cobimetinib cobimetinib an exelixisdiscovered compound is a selective inhibitor of mek part of the rasrafmekerk pathway that is frequently dysregulated in human tumors cobimetinib is being developed by genentech a member of the roche group under a collaboration agreement with exelixis and is the subject of a broad clinical development program in combination with a variety of investigational and approved therapies cobimetinib is now approved in multiple countries including the united states european union switzerland canada australia and brazil to treat specific forms of braf mutationpositive unresectable or metastatic melanoma in combination with vemurafenib the trade name for cobimetinib is cotellic® for more information on cotellic including important safety information please click here xl xl is a highly potent orally bioavailable atpcompetitive inhibitor of hsp a molecular chaperone protein that affects the activity and stability of a range of key regulatory proteins including kinases such as braf met and vegfr exelixis discovered xl and owns the compound exclusively partnered compounds we have established multiple partnerships and collaborations with other leading pharmaceutical and biopharmaceutical companies these partnerships are designed to advance the development of a variety of potential therapies for cancer and other serious diseases about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site pipeline cabozantinib cobimetinib xl partnered compounds  exelixis inc    website design hane chow inc privacy terms of use microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft exelnasdaq gs stock quote  exelixis inc  bloomberg markets error could not add to watchlist x  watchlist exelixis inc exelus nasdaq gs usd   as of  am edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  top  biotech stocks for   investopedia  will exelixis break out from key resistance  investopedia  exelixis q net  cents a share vs loss last year  investopedia  exelixis in cancer deals with roche bristol myers  investopedia  exelixis takeda sign japanese cancer drug deal  investopedia there are currently no news stories for this ticker please check back later  exelixis announces settlement of dispute with genentech regarding companies’ collaboration agreement for cobimetinib  exelixis to release second quarter  financial results on wednesday august    exelixis and bristolmyers squibb initiate phase  trial of opdivo® in combination with cabometyx™ or opdivo and yervoy® in  exelixis repays deerfield notes one year ahead of maturity date addressing last major source of indebtedness  biopharma stock breakouts with significant developments and market activity  ipsen and its partner exelixis announce independent radiology committee review confirms results from phase  cabosun trial of  exelixis announces independent radiology committee review confirms results from cabosun the phase  trial of cabozantinib  exelixis announces initiation of phase b trial of cabozantinib in combination with atezolizumab in patients with locally  exelixis to present at the william blair  co th annual growth stock conference on june   exelixis reports inducement grants under nasdaq listing rule c there are currently no press releases for this ticker please check back later profile exelixis inc is a developmentstage biotechnology company dedicated to the discovery and development of smallmolecule therapeutics for the treatment of cancer and other serious diseases the company is building a portfolio of compounds it believes could become pharmaceutical products exelixis has strategic alliances with pharmaceutical and biotechnology companies address  east grand avenuesouth san francisco ca united states phone  website wwwexelixiscom executives board members michael m morrissey presidentceo gisela m schwab presproduct devchief medical ofcr christopher j senner exec vpcfo jeffrey j hessekiel exec vpsecygeneral counsel peter lamb exec vpscientificchief scientific ofcr show more pipeline  exelixis pipeline the exelixis pipeline includes our lead compounds cabozantinib and cobimetinib as well as other programs that are the subject of partnerships and collaborations with other biopharmaceutical companies an additional whollyowned compound xl is the subject of ongoing clinical research through our investigatorsponsored trial program safety and efficacy for these compounds in the unapproved uses or indications described below have not yet been established cabozantinib exelixis focuses its internal development efforts primarily upon cabozantinib a targeted agent that inhibits the activity of receptor tyrosine kinases including met axl vegf receptors and ret these receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis metastasis tumor angiogenesis and maintenance of the tumor microenvironment exelixis discovered cabozantinib internally and maintains exclusive rights to commercialize the product in the united states outside of the united states ipsen has exclusive commercialization and development rights for current and future cabozantinib indications except in japan where exelixis has granted exclusive rights to takeda exelixis and its partners are collaborating on the global development plan for cabozantinib and ipsen and takeda are responsible for the development work supporting cabozantinib in their respective regions for information on approved uses of cabozantinib please visit our medicines page cobimetinib cobimetinib an exelixisdiscovered compound is a selective inhibitor of mek part of the rasrafmekerk pathway that is frequently dysregulated in human tumors cobimetinib is being developed by genentech a member of the roche group under a collaboration agreement with exelixis and is the subject of a broad clinical development program in combination with a variety of investigational and approved therapies cobimetinib is now approved in multiple countries including the united states european union switzerland canada australia and brazil to treat specific forms of braf mutationpositive unresectable or metastatic melanoma in combination with vemurafenib the trade name for cobimetinib is cotellic® for more information on cotellic including important safety information please click here xl xl is a highly potent orally bioavailable atpcompetitive inhibitor of hsp a molecular chaperone protein that affects the activity and stability of a range of key regulatory proteins including kinases such as braf met and vegfr exelixis discovered xl and owns the compound exclusively partnered compounds we have established multiple partnerships and collaborations with other leading pharmaceutical and biopharmaceutical companies these partnerships are designed to advance the development of a variety of potential therapies for cancer and other serious diseases about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site pipeline cabozantinib cobimetinib xl partnered compounds  exelixis inc    website design hane chow inc privacy terms of use microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft exelixis learn more learn more learn more welcome exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer over the past decade we have established a broad development platform laying the foundation for our continued efforts to bring new therapies for cancer to patients in need to date three medicines discovered at exelixis have received regulatory approval to treat different types of cancer we are steadfast in our commitment to excellence in all aspects of our business and are dedicated to improving the care of and outcomes for patients in need of new treatment options stock nasdaq exel jul   am edt price   volume  shares  minute delay exelixis in the news jul   exelixis announces settlement of dispute with genentech regarding companies’ collaboration agreement for cobimetinib jul   exelixis to release second quarter  financial results on wednesday august   jul   exelixis and bristolmyers squibb initiate phase  trial of opdivo® in combination with cabometyx™ or opdivo and yervoy® in combination with cabometyx versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma jun   exelixis repays deerfield notes one year ahead of maturity date addressing last major source of indebtedness more news exelixis annual report  teamwork is a constant across drug development and patient care learn about the company’s performance in  and how the exelixis team and the broader oncology community come together in their collective effort to help patients learn more download pdf about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site  exelixis inc    website design hane chow inc privacy terms of use microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft press releases  exelixis about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site investors  media management and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir  exelixis inc    website design hane chow inc privacy terms of use careers  exelixis careers every biopharmaceutical company has a vision of improving patients’ lives come be part of a team that has made that vision a reality our successful commercialization of cabozantinib is evidence of our team’s talent dedication and ability to set and achieve goals individually and as an organization our culture supports and nurtures individual achievement while fostering a strong sense of community and shared purpose our senior management team is committed to helping each member of the exelixis team contribute to our success as a company while advancing our employees skills knowledge and expertise our employees strive to make a positive impact in their careers and their communities and we are proud to support their efforts through a variety of corporate philanthropy education and fundraising programs together the exelixis team has already brought a new treatment option to patients living with medullary thyroid cancer and we are using this foundation to help improve the care and outcomes of other cancer patients headquartered in south san francisco california exelixis has a dedicated workforce that shares a commitment to making a positive difference in the lives of patients with cancer and other serious diseases   exelixis is an equal opportunity employer and does not discriminate against applicants due to race ethnicity gender veteran status or on the basis of disability or any other federal state or local protected class for more information about equal employment opportunity protections view the eeo is the law poster notice to recruitersstaffing agencies recruiters and staffing agencies should not contact exelixis inc through this page we require that all recruiters and staffing agencies have a signed contract on file any resumes submitted through the web site or directly by recruiters or staffing agencies will be considered unsolicited and the company will not be responsible for any related fees about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site careers job opportunities  exelixis inc    website design hane chow inc privacy terms of use exelixis learn more learn more learn more welcome exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer over the past decade we have established a broad development platform laying the foundation for our continued efforts to bring new therapies for cancer to patients in need to date three medicines discovered at exelixis have received regulatory approval to treat different types of cancer we are steadfast in our commitment to excellence in all aspects of our business and are dedicated to improving the care of and outcomes for patients in need of new treatment options stock nasdaq exel jul   am edt price   volume  shares  minute delay exelixis in the news jul   exelixis announces settlement of dispute with genentech regarding companies’ collaboration agreement for cobimetinib jul   exelixis to release second quarter  financial results on wednesday august   jul   exelixis and bristolmyers squibb initiate phase  trial of opdivo® in combination with cabometyx™ or opdivo and yervoy® in combination with cabometyx versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma jun   exelixis repays deerfield notes one year ahead of maturity date addressing last major source of indebtedness more news exelixis annual report  teamwork is a constant across drug development and patient care learn about the company’s performance in  and how the exelixis team and the broader oncology community come together in their collective effort to help patients learn more download pdf about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site  exelixis inc    website design hane chow inc privacy terms of use exelixis learn more learn more learn more welcome exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer over the past decade we have established a broad development platform laying the foundation for our continued efforts to bring new therapies for cancer to patients in need to date three medicines discovered at exelixis have received regulatory approval to treat different types of cancer we are steadfast in our commitment to excellence in all aspects of our business and are dedicated to improving the care of and outcomes for patients in need of new treatment options stock nasdaq exel jul   am edt price   volume  shares  minute delay exelixis in the news jul   exelixis announces settlement of dispute with genentech regarding companies’ collaboration agreement for cobimetinib jul   exelixis to release second quarter  financial results on wednesday august   jul   exelixis and bristolmyers squibb initiate phase  trial of opdivo® in combination with cabometyx™ or opdivo and yervoy® in combination with cabometyx versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma jun   exelixis repays deerfield notes one year ahead of maturity date addressing last major source of indebtedness more news exelixis annual report  teamwork is a constant across drug development and patient care learn about the company’s performance in  and how the exelixis team and the broader oncology community come together in their collective effort to help patients learn more download pdf about usmanagement board of directors collaborations locations contact us medicines pipelinecabozantinib cobimetinib xl partnered compounds clinical trialsexelixis clinical trials national cancer institute sponsored trials investigator sponsored trials faqs about clinical trials medical informationaccess to investigational medications investors  mediamanagement and board corporate governance stock information analyst coverage earnings estimates earnings ratings annual reports sec filings press releases event calendar media resources information request investor faqs contact ir responsibilityethics and compliance careersjob opportunities search this site  exelixis inc    website design hane chow inc privacy terms of use exelixis inc  product pipeline review   purchase this report exelixis inc  product pipeline review   published pages publisher report code may   global markets direct asdr published may      pages       publisher  global markets direct     report code  asdr descriptiondesc contentcont figures  tablesfiguresfig free samplesample summarythe new report ‘exelixis inc  product pipeline review  ’ provides an overview of the exelixis inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of exelixis inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsthis report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources and put together drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope   • the report provides brief overview of exelixis inc including business description key information and facts and its locations and subsidiaries   • the report reviews current pipeline of exelixis inc’s human therapeutic division and enlists all their major and minor projects   • the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones    • special feature on outlicensed and partnered product portfolio   • the report summarizes all the dormant and discontinued pipeline projects   • latest company statement    • latest news and deals relating to the exelixis inc’s pipeline productsreasons to buy   • evaluate exelixis inc’s strategic position with total access to detailed information on its product pipeline   • assess the growth potential of exelixis inc in its therapy areas of focus   • identify new drug targets and therapeutic classes in the exelixis inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas   • exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps   • develop strategic initiatives by understanding the focus areas of exelixis inc and exploit collaboration and partnership opportunities   • identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage   • plan mergers and acquisitions effectively by identifying the most promising pipeline of exelixis inc   • develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope   • explore the dormant and discontinued projects of exelixis inc and identify potential opportunities in those areas   • avoid intellectual property rights related issues purchase this report us  euro € gbp £ user pdf us  site pdf us  enterprise pdf us  add to cart   lowest price guarantee license and delivery order process  question about this report this report can be of interest as well nonsmall cell lung cancer nsclc drugs market forecast  published june   report code asdr mark your calendar nd drug development forum  september   september boston united states search engine marketing sem  bing ads skip to content sign upsign in   you run your business well help find your customers bing ads can help build your business and drive your success spend  and get  in advertising credit† †offer details get  in search advertising when you spend  in bing ads coupon code class first name last name email your website url business phone required microsoft may contact you to provide updates and special offers about bing ads you can unsubscribe at any time to learn more you can read the privacy statement type the code from the image enter security code   × get  in search advertising when you spend  in bing ads †offer details offer expires december   valid only for new bing ads customers who are first party recipients of the offer email a new bing ads customer is one that has not advertised on bing ads before enter promotional coupon code and spend  applies to threshold and prepaid accounts to receive  in bing ads credits limit one promotion code per new bing ads customer promotional code must be redeemed within thirty  days of bing ads new customer account creation ad campaign costs accrued before receiving a credit as well as costs accrued after all credits are used will be charged to the payment method associated with the bing ads account if customer payment fails the coupon amount will not be applied ads will continue to run and accrue costs after any promotional credit has been used up any portion of the credit not used within ninety  days of credit redemption will expire and cant be carried over even if the bing ads customer switches their payment method offer valid only to residents of the united states in order for the offer to be valid a form of payment must be entered into your account prior to redemption of the promotional code and prior to your account going live to take advantage of the credit this offer may not be combined with any other offer promotional code coupon or discount separated redeemed for cash transferred sold or bartered microsoft in its sole discretion can close your account for any suspected coupon abuse refund of the  is not permitted see bing ads terms and conditions for more details at signup other terms and conditions may apply microsoft reserves the right to cancel change or suspend this offer at any time without notice see how bing ads works customers search customers see your ad customers contact you watch how bing ads works     × how bing ads works help more customers find you see how bing can attract customers your google adwords campaigns cant reach  million searchers on the bing network tap into  of the search marketplace get in front of searchers who spend  percent more than the average internet searcher powerful network powerful benefits reach across devicesconnect with customers looking for your business anytime anywhere on any device go global or localreach people in the bing network everywhere or focus on cities counties and areas within a certain distance from your business easy to importif youre already using another product like google adwords its easy to pull that campaign into bing ads you control your costs  free signupjoin bing ads for free and control your account at every step  only pay for clickspay just when customers click on your ad no click no charge  no minimum feestart advertising with a budget that works best for your business   the advantage we gain in cost per click gives us a great return on investment — more than  percent better than google adwords scott redgate search engine marketing manager — cj pony parts by using bing ads features like image extensions and sitelink extensions this auto parts retailer races to convert customers and beat its competition  read about driving more conversions   we might not get as much of the volume as with google adwords but the volume of the traffic that we get converts really well at a lower cost scott schult executive vice president of marketing — myrtle beach area convention and visitors bureau the myrtle beach area convention and visitors bureau uses bing ads to drive site traffic and tourism at lower cost  read about getting better roi better results for less cost thats as simple as i can make it if i look at the quality of the traffic we get for the dollars we spend on bing ads our roi is fantastic alex littlewood ceo   motoroso motoroso a market network for auto enthusiasts gets better results for less cost and reaches a highvalue audience with bing ads  read about attracting quality traffic   import your adwords campaigns save time by importing your google adwords campaigns into bing ads to get ads live quickly sign in with your microsoft account or create one to get started on bing ads from within the bing ads interface select the import from google adwords option enter your google adwords credentials and select the campaign you want to import preview your ad get found online with search engine marketing make the most of your marketing dollars and drive customers to your business see how bing ads can work for you get started today give us a few details about your business to create a bing ads account and get it up and running   sign up get started with bing ads signing up is always free faq is bing ads right for me is bing ads right for my business all types of businesses find value and success with bing ads whether youre focused on local calls and foot traffic or want to drive traffic to your website from across the country or around the world bing ads has solutions for you i already appear in search results for free why should i pay for advertising your current customers may search for your business by name aiming it easy to find you in search results but customers youve yet to reach are more likely searching for general terms that wouldnt necessarily bring up your business in search results advertising next to relevant bing search results puts your business front and center with interested customers you otherwise might not reach what is the difference between seo and sem which one is right for me search engine optimization seo is adjusting your website to improve your natural ranking in search results you cannot pay to improve your website ranking on bing or yahoo thus we often refer to these results and unpaid or organic search results clicks from seo are free but seo also requires technical expertise and involves some factors over which you have only limited control search engine marketing sem is paid advertising that appears next to or above unpaid or organic search results these paid ads are purchased through bing ads you pay for sem clicks but sem gives you more control over when your website appears on results pages and you decide how much you want to pay and you can measure which ads are working and quickly improve your results you dont have to choose between seo and sem you can do both if my time is limited should i still try bing ads yes call a bing ads specialist at and we’ll set up your first campaign for you for free we’ll give you tips on getting the most out of your ads and set you up for success we’re here to help about bing ads where does my ad appear your ads could appear on the top or to the right of bing yahoo and msn search results and you can choose to target your ads to different geographic regions times or days of the week and even demographics what determines my ad position bing ads is a payperclick ppc advertising system you bid based on how much you are willing to pay per each click on your ad because webpages have a limited number of places to show ads we auction those spaces you are bidding against other advertisers to get your ads into the space you want so if you bid on the keyword shoe you will have to beat the bids of the other advertisers who are also bidding on shoe you determine how much you are willing to bid your ad position is based on several things including how closely your ad and website fit with the terms that are searched relevance how your bid compares to other bids in the bing ads auction how strongly your ad has performed in the past and how often it has been clicked clickthrough rate the stronger you are in these areas the better your chances of winning the top ad position how to use bing ads how can i use bing ads to drive more people to my website here are some tips to get better results review your budget and bid strategy if your ad keeps pausing your budget limit may be set too low competitive bids help your ad stay in a strong position to catch eyes and get more clicks to your website expand your targeting both for location and for devices computer mobile and tablet make sure your ads and website are relevant to the keywords you bid on would someone searching your terms expect to see and ad for your business how can i keep my costs down while your first instinct may be to lower your budget first try lowering your maximum bids yes this could mean fewer customers visit your site but if you increase your quality score and build ads with a strong performance history you may be able to win a good ad position with a lower bid that would lower your costperclick and help stretch your budget how do i know if bing ads is working view a wide range of performance trends in your account to quickly see key stats ad clicks the number of times your ad appeared impressions spend average costperclick clickthrough rate average ad position cost per acquisition and conversions you can also run performance reports to get insights into how well your campaigns are doing can i run more than one ad yes in fact we encourage it only one ad will show at a time but running multiple ads lets you test different approaches to see whats working best with your target customers frequently businesses try out different ads for specific products or pages getting started with bing ads how do i get started sign up for bing ads which keywords should i choose you have a few options to help choose your keywords first youll want to think of the terms one of your customers might use to search for your products and offerings those search terms are a great starting point then you can use tools right in your account to find more keywords within bing ads click campaigns on the top of the page click the keywords tab and then click add keywords this will let you search for new keywords based on one you enter search a website for keywords search your destination urls for keywords how can i write a good ad here are a few tips that can help make your ad stand out keep your ads relevant one way to improve relevance is to use your customers most popular search terms in your ad titles and txt describe what sets your product apart use your customers language use words and writing tone that are likely to attract your typical customer be specific this clearer and more specific your offering the better for example rather than big discount specify and exact percentage such as  percent off give customers a reason to click your ad right now offer a specific call to action such as encouraging customers to request a brochure or consultation download a free ebook subscribe to a newsletter or take advantage of a limitedtime discount sign up with bing ads to get started